Viridian Therapeutics (VRDN) Competitors $12.80 -0.50 (-3.76%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$12.62 -0.18 (-1.41%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN vs. RDNT, BTSG, SHC, SGRY, PRVA, CON, LFST, WGS, VCYT, and PGNYShould you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), LifeStance Health Group (LFST), GeneDx (WGS), Veracyte (VCYT), and Progyny (PGNY). These companies are all part of the "healthcare" industry. Viridian Therapeutics vs. RadNet BrightSpring Health Services Sotera Health Surgery Partners Privia Health Group Concentra Group Holdings Parent LifeStance Health Group GeneDx Veracyte Progyny Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability. Which has more volatility and risk, VRDN or RDNT? Viridian Therapeutics has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Does the MarketBeat Community prefer VRDN or RDNT? RadNet received 282 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 78.72% of users gave Viridian Therapeutics an outperform vote while only 66.29% of users gave RadNet an outperform vote. CompanyUnderperformOutperformViridian TherapeuticsOutperform Votes7478.72% Underperform Votes2021.28% RadNetOutperform Votes35666.29% Underperform Votes18133.71% Does the media prefer VRDN or RDNT? In the previous week, RadNet had 12 more articles in the media than Viridian Therapeutics. MarketBeat recorded 22 mentions for RadNet and 10 mentions for Viridian Therapeutics. RadNet's average media sentiment score of 1.25 beat Viridian Therapeutics' score of 0.94 indicating that RadNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive RadNet 15 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts rate VRDN or RDNT? Viridian Therapeutics currently has a consensus target price of $35.70, indicating a potential upside of 178.91%. RadNet has a consensus target price of $69.75, indicating a potential upside of 31.41%. Given Viridian Therapeutics' higher possible upside, research analysts plainly believe Viridian Therapeutics is more favorable than RadNet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viridian Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75RadNet 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Do insiders & institutionals have more ownership in VRDN or RDNT? 77.9% of RadNet shares are owned by institutional investors. 0.7% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 5.1% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is VRDN or RDNT more profitable? RadNet has a net margin of -0.25% compared to Viridian Therapeutics' net margin of -85,127.16%. RadNet's return on equity of 4.29% beat Viridian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viridian Therapeutics-85,127.16% -70.12% -41.49% RadNet -0.25%4.29%1.45% Which has preferable earnings and valuation, VRDN or RDNT? RadNet has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViridian Therapeutics$302K3,453.67-$237.73M-$3.77-3.40RadNet$1.83B2.15$3.04M$0.031,769.33 SummaryRadNet beats Viridian Therapeutics on 14 of the 19 factors compared between the two stocks. Remove Ads Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRDN vs. The Competition Export to ExcelMetricViridian TherapeuticsMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$2.86B$5.33B$7.57BDividend YieldN/A31.37%5.11%4.33%P/E Ratio-2.9713.3521.8317.81Price / Sales3,453.67187.25379.4694.58Price / CashN/A57.5638.1534.64Price / Book2.864.556.454.00Net Income-$237.73M-$22.21M$3.20B$247.23M7 Day Performance16.15%7.35%6.60%7.26%1 Month Performance-19.60%-1.19%-8.50%-6.26%1 Year Performance-18.16%6.30%10.33%-0.18% Viridian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRDNViridian Therapeutics1.0287 of 5 stars$12.80-3.8%$35.70+178.9%-18.2%$1.04B$302,000.00-2.9750News CoverageRDNTRadNet3.8288 of 5 stars$49.29+1.2%$73.25+48.6%+11.0%$3.65B$1.83B-704.048,970Positive NewsHigh Trading VolumeBTSGBrightSpring Health Services2.9237 of 5 stars$17.28+0.8%$21.67+25.4%+64.4%$3.02B$11.27B-66.4635,000News CoverageGap DownSHCSotera Health2.4134 of 5 stars$10.23-1.1%$16.00+56.4%-4.6%$2.90B$1.10B40.923,000Gap DownSGRYSurgery Partners2.7624 of 5 stars$20.51-2.8%$36.63+78.6%-17.9%$2.62B$3.11B-42.7313,500Positive NewsGap DownPRVAPrivia Health Group3.7677 of 5 stars$21.48-2.2%$26.67+24.1%+31.8%$2.59B$1.74B214.82810Analyst ForecastHigh Trading VolumeCONConcentra Group Holdings ParentN/A$20.19-2.1%$28.50+41.2%N/A$2.57B$1.90B13.3711,000Positive NewsGap DownLFSTLifeStance Health Group1.9107 of 5 stars$6.51-2.0%$8.50+30.6%+16.6%$2.50B$1.25B-25.046,640Positive NewsGap DownWGSGeneDx1.8312 of 5 stars$84.77+5.9%$72.33-14.7%+934.6%$2.38B$305.45M-43.251,200Positive NewsVCYTVeracyte4.0071 of 5 stars$29.53+2.0%$43.40+47.0%+64.0%$2.30B$445.76M-196.87790Short Interest ↑PGNYProgyny1.5644 of 5 stars$21.43-5.2%$23.64+10.3%-35.5%$1.83B$1.17B36.95310Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors PRVA Competitors CON Competitors LFST Competitors WGS Competitors VCYT Competitors PGNY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRDN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRDN Stock Free VRDN Stock Alerts